Oral iron for people with chronic kidney disease
Referencias
Additional references
Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney International 2004;65(6):2279‐89. [MEDLINE: 15149341]
Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology 2006;26(5):445‐54. [MEDLINE: 17035697]
Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD007857.pub2]
Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988‐1994). Archives of Internal Medicine 2002;162(12):1401‐8. [MEDLINE: 12076240]
Camaschella C, Schrier SL. Regulation of iron balance. In: UpToDate, Mentzer WC (Ed). UpToDate, Waltham, MA (accessed 27 November 2014).
Dmitrieva O, de Lusignan S, Macdougall IC, Gallagher H, Tomson C, Harris K, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrology 2013;14:24. [MEDLINE: 23351270]
Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrology Dialysis Transplantation 2014;29(2):255‐9. [MEDLINE: 24166458]
Galloway MJ, Smellie WS. Investigating iron status in microcytic anaemia. BMJ 2006;333(7572):791‐3. [MEDLINE: 17038737]
Hallberg L. Bioavailability of dietary iron in man. Annual Review of Nutrition 1981;1:123‐47. [MEDLINE: 6764713]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: 12958120]
Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hodson EM, Craig JC. Oral iron for patients receiving dialysis: What is the evidence?. Seminars in Dialysis 2014;27(1):8‐10. [MEDLINE: 24400800]
Horl WH. Clinical aspects of iron use in the anemia of kidney disease. Journal of the American Society of Nephrology 2007;18(2):382‐93. [MEDLINE: 17229908]
Hsu CY, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. Journal of the American Society of Nephrology 2002;13(11):2783‐6. [MEDLINE: 12397050]
Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, Isbel NM. Oral versus intravenous iron supplementation in peritoneal dialysis patients. Peritoneal Dialysis International 2001;21 Suppl 3:S231‐5. [MEDLINE: 11887827]
Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014;123(5):615‐24. [MEDLINE: 24297872]
KDIGO. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements 2012;2(4):1‐64. [DOI: 10.1038/kisup.2012.37]
KDOQI. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. American Journal of Kidney Diseases2006; Vol. 47, issue 5 Suppl 3:S11‐145. [MEDLINE: 16678659]
Kooistra MP, Marx JJ. The absorption of iron is disturbed in recombinant human erythropoietin‐treated peritoneal dialysis patients. Nephrology Dialysis Transplantation 1998;13(10):2578‐82. [MEDLINE: 9794563]
Macdougall IC. Iron supplementation in the non‐dialysis chronic kidney disease (ND‐CKD) patient: oral or intravenous?. Current Medical Research & Opinion 2010;26(2):473–82. [MEDLINE: 20014980]
Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation 2014;29(4):843–50. [MEDLINE: 24170814]
Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clinical Nephrology 1997;48(1):34‐40. [MEDLINE: 9247776]
McFarlane S, Chen S, Whaley‐Connell AT, Sowers JR, Vassalotti JA, et al. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999‐2004. American Journal of Kidney Diseases 2008;51(4 Suppl 2):S46‐55. [MEDLINE: 18359408]
Nagaraju SP, Cohn A, Akbari A, Davis JL, Zimmerman DL. Heme iron polypeptide for the treatment of iron deficiency anemia in non‐dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrology 2013;14:64. [MEDLINE: 23514036]
New JP, Aung T, Baker PG, Yongsheng G, Pylypczuk R, Houghton J, et al. The high prevalence of unrecognized anaemia in patients with diabetes and chronic kidney disease: a population based study. Diabetic Medicine 2008;25(5):564–9. [MEDLINE: 18445169]
National Institute for Health Care Excellence. Anaemia management in people with chronic kidney disease. NICE guidelines 114, 2011. www.nice.org.uk/guidance/cg114 (accessed 27 November 2014).
National Institutes of Health. Office of Dietary Supplements. Iron. Dietary supplement fact sheet. ods.od.nih.gov/factsheets/Iron‐HealthProfessional (accessed 27 November 2014).
Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. Journal of the American Society of Nephrology 1999;10(8):1793‐800. [MEDLINE: 10446948]
Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE 2014;9(1):e84943. [EMBASE: 12014130420]
Tsuchida A, Paudyal B, Paudyal P, Ishii Y, Hiromura K, Nojima Y, et al. Effectiveness of oral iron to manage anemia in long‐term hemodialysis patients with the use of ultrapure dialysate. Experimental & Therapeutic Medicine 2010;1(5):777‐81. [EMBASE: 2010419867]
Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S, United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis‐dependent CKD. Kidney International 2005;68(6):2846‐56. [MEDLINE: 16316362]
Vychytil A, Haag‐Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney international ‐ Supplement 1999;69:S71‐8. [MEDLINE: 10084290]
Weiss G, Gordeuk VR. Benefits and risks of iron therapy for chronic anaemias. European Journal of Clinical Investigation 2005;35 Suppl 3:36‐45. [MEDLINE: 16281957]
WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMD/NHD/MNM/11.1). www.who.int/vmnis/indicators/haemoglobin.pdf (accessed 27 November 2014).
Wong G, Howard K, Hodson E, Irving M, Craig JC. An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis. Nephrology Dialysis Transplantation 2013;28(2):413–20. [MEDLINE: 23182811]
